Predictors of Responses to Corticosteroids for Cancer-Related Fatigue in Advanced Cancer Patients

A Multicenter, Prospective, Observational Study

Naoki Matsuo, Tatsuya Morita, Yoshinobu Matsuda, Kenichiro Okamoto, Yoshihisa Matsumoto, Keisuke Kaneishi, Takuya Odagiri, Hiroki Sakurai, Hideki Katayama, Ichiro Mori, Hirohide Yamada, Hiroaki Watanabe, Taro Yokoyama, Takashi Yamaguchi, Tomohiro Nishi, Akemi Shirado, Shuji Hiramoto, Toshio Watanabe, Hiroyuki Kohara, Satofumi Shimoyama & 4 others Etsuko Aruga, Mika Baba, Koki Sumita, Satoru Iwase

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Context Although corticosteroids are widely used to relieve cancer-related fatigue (CRF), information regarding the factors predicting responses to corticosteroids remains limited. Objectives The aim of this study was to identify potential factors predicting responses to corticosteroids for CRF in advanced cancer patients. Methods Inclusion criteria for this multicenter, prospective, observational study were patients who had metastatic or locally advanced cancer and had a fatigue intensity score of 4 or more on a 0–10 Numerical Rating Scale (NRS). Univariate and multivariate analyses were conducted to identify the factors predicting two-point reduction or more in NRS on day 3. Results Among 179 patients who received corticosteroids, 86 (48%; 95% CI 41%–56%) had a response with two-point reduction or more. Factors that significantly predicted responses were performance status score of 3 or more, Palliative Performance Scale score more than 40, absence of ascites, absence of drowsiness, absence of depression, serum albumin level greater than 3 mg/dL, serum sodium level greater than 135 mEq/L, and baseline NRS score greater than 5. A multivariate analysis showed that the independent factors predicting responses were baseline NRS score greater than 5 (odds ratio [OR] 6.6, 95% CI 2.8–15.4), Palliative Performance Scale score more than 40 (OR 4.4, 95% CI 2.1–9.3), absence of drowsiness (OR 3.4, 95% CI 1.7–6.9), absence of ascites (OR 2.3, 95% CI 1.1–4.7), and absence of pleural effusion (OR 2.2, 95% CI 1.0–5.0). Conclusion Treatment responses to corticosteroids for CRF may be predicted by baseline symptom intensity, performance status, drowsiness, and severity of fluid retention symptoms. Larger prospective studies are needed to confirm these results.

Original languageEnglish
Pages (from-to)64-72
Number of pages9
JournalJournal of Pain and Symptom Management
Volume52
Issue number1
DOIs
Publication statusPublished - Jul 1 2016
Externally publishedYes

Fingerprint

Observational Studies
Fatigue
Adrenal Cortex Hormones
Odds Ratio
Prospective Studies
Sleep Stages
Neoplasms
Ascites
Multivariate Analysis
Pleural Effusion
Serum Albumin
Sodium
Depression
Serum
Therapeutics

Keywords

  • cancer
  • corticosteroids
  • Fatigue
  • palliative care
  • predictors

ASJC Scopus subject areas

  • Nursing(all)
  • Clinical Neurology
  • Anesthesiology and Pain Medicine

Cite this

Predictors of Responses to Corticosteroids for Cancer-Related Fatigue in Advanced Cancer Patients : A Multicenter, Prospective, Observational Study. / Matsuo, Naoki; Morita, Tatsuya; Matsuda, Yoshinobu; Okamoto, Kenichiro; Matsumoto, Yoshihisa; Kaneishi, Keisuke; Odagiri, Takuya; Sakurai, Hiroki; Katayama, Hideki; Mori, Ichiro; Yamada, Hirohide; Watanabe, Hiroaki; Yokoyama, Taro; Yamaguchi, Takashi; Nishi, Tomohiro; Shirado, Akemi; Hiramoto, Shuji; Watanabe, Toshio; Kohara, Hiroyuki; Shimoyama, Satofumi; Aruga, Etsuko; Baba, Mika; Sumita, Koki; Iwase, Satoru.

In: Journal of Pain and Symptom Management, Vol. 52, No. 1, 01.07.2016, p. 64-72.

Research output: Contribution to journalArticle

Matsuo, N, Morita, T, Matsuda, Y, Okamoto, K, Matsumoto, Y, Kaneishi, K, Odagiri, T, Sakurai, H, Katayama, H, Mori, I, Yamada, H, Watanabe, H, Yokoyama, T, Yamaguchi, T, Nishi, T, Shirado, A, Hiramoto, S, Watanabe, T, Kohara, H, Shimoyama, S, Aruga, E, Baba, M, Sumita, K & Iwase, S 2016, 'Predictors of Responses to Corticosteroids for Cancer-Related Fatigue in Advanced Cancer Patients: A Multicenter, Prospective, Observational Study', Journal of Pain and Symptom Management, vol. 52, no. 1, pp. 64-72. https://doi.org/10.1016/j.jpainsymman.2016.01.015
Matsuo, Naoki ; Morita, Tatsuya ; Matsuda, Yoshinobu ; Okamoto, Kenichiro ; Matsumoto, Yoshihisa ; Kaneishi, Keisuke ; Odagiri, Takuya ; Sakurai, Hiroki ; Katayama, Hideki ; Mori, Ichiro ; Yamada, Hirohide ; Watanabe, Hiroaki ; Yokoyama, Taro ; Yamaguchi, Takashi ; Nishi, Tomohiro ; Shirado, Akemi ; Hiramoto, Shuji ; Watanabe, Toshio ; Kohara, Hiroyuki ; Shimoyama, Satofumi ; Aruga, Etsuko ; Baba, Mika ; Sumita, Koki ; Iwase, Satoru. / Predictors of Responses to Corticosteroids for Cancer-Related Fatigue in Advanced Cancer Patients : A Multicenter, Prospective, Observational Study. In: Journal of Pain and Symptom Management. 2016 ; Vol. 52, No. 1. pp. 64-72.
@article{084c550905f749079c06af62f18d4af3,
title = "Predictors of Responses to Corticosteroids for Cancer-Related Fatigue in Advanced Cancer Patients: A Multicenter, Prospective, Observational Study",
abstract = "Context Although corticosteroids are widely used to relieve cancer-related fatigue (CRF), information regarding the factors predicting responses to corticosteroids remains limited. Objectives The aim of this study was to identify potential factors predicting responses to corticosteroids for CRF in advanced cancer patients. Methods Inclusion criteria for this multicenter, prospective, observational study were patients who had metastatic or locally advanced cancer and had a fatigue intensity score of 4 or more on a 0–10 Numerical Rating Scale (NRS). Univariate and multivariate analyses were conducted to identify the factors predicting two-point reduction or more in NRS on day 3. Results Among 179 patients who received corticosteroids, 86 (48{\%}; 95{\%} CI 41{\%}–56{\%}) had a response with two-point reduction or more. Factors that significantly predicted responses were performance status score of 3 or more, Palliative Performance Scale score more than 40, absence of ascites, absence of drowsiness, absence of depression, serum albumin level greater than 3 mg/dL, serum sodium level greater than 135 mEq/L, and baseline NRS score greater than 5. A multivariate analysis showed that the independent factors predicting responses were baseline NRS score greater than 5 (odds ratio [OR] 6.6, 95{\%} CI 2.8–15.4), Palliative Performance Scale score more than 40 (OR 4.4, 95{\%} CI 2.1–9.3), absence of drowsiness (OR 3.4, 95{\%} CI 1.7–6.9), absence of ascites (OR 2.3, 95{\%} CI 1.1–4.7), and absence of pleural effusion (OR 2.2, 95{\%} CI 1.0–5.0). Conclusion Treatment responses to corticosteroids for CRF may be predicted by baseline symptom intensity, performance status, drowsiness, and severity of fluid retention symptoms. Larger prospective studies are needed to confirm these results.",
keywords = "cancer, corticosteroids, Fatigue, palliative care, predictors",
author = "Naoki Matsuo and Tatsuya Morita and Yoshinobu Matsuda and Kenichiro Okamoto and Yoshihisa Matsumoto and Keisuke Kaneishi and Takuya Odagiri and Hiroki Sakurai and Hideki Katayama and Ichiro Mori and Hirohide Yamada and Hiroaki Watanabe and Taro Yokoyama and Takashi Yamaguchi and Tomohiro Nishi and Akemi Shirado and Shuji Hiramoto and Toshio Watanabe and Hiroyuki Kohara and Satofumi Shimoyama and Etsuko Aruga and Mika Baba and Koki Sumita and Satoru Iwase",
year = "2016",
month = "7",
day = "1",
doi = "10.1016/j.jpainsymman.2016.01.015",
language = "English",
volume = "52",
pages = "64--72",
journal = "Journal of Pain and Symptom Management",
issn = "0885-3924",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Predictors of Responses to Corticosteroids for Cancer-Related Fatigue in Advanced Cancer Patients

T2 - A Multicenter, Prospective, Observational Study

AU - Matsuo, Naoki

AU - Morita, Tatsuya

AU - Matsuda, Yoshinobu

AU - Okamoto, Kenichiro

AU - Matsumoto, Yoshihisa

AU - Kaneishi, Keisuke

AU - Odagiri, Takuya

AU - Sakurai, Hiroki

AU - Katayama, Hideki

AU - Mori, Ichiro

AU - Yamada, Hirohide

AU - Watanabe, Hiroaki

AU - Yokoyama, Taro

AU - Yamaguchi, Takashi

AU - Nishi, Tomohiro

AU - Shirado, Akemi

AU - Hiramoto, Shuji

AU - Watanabe, Toshio

AU - Kohara, Hiroyuki

AU - Shimoyama, Satofumi

AU - Aruga, Etsuko

AU - Baba, Mika

AU - Sumita, Koki

AU - Iwase, Satoru

PY - 2016/7/1

Y1 - 2016/7/1

N2 - Context Although corticosteroids are widely used to relieve cancer-related fatigue (CRF), information regarding the factors predicting responses to corticosteroids remains limited. Objectives The aim of this study was to identify potential factors predicting responses to corticosteroids for CRF in advanced cancer patients. Methods Inclusion criteria for this multicenter, prospective, observational study were patients who had metastatic or locally advanced cancer and had a fatigue intensity score of 4 or more on a 0–10 Numerical Rating Scale (NRS). Univariate and multivariate analyses were conducted to identify the factors predicting two-point reduction or more in NRS on day 3. Results Among 179 patients who received corticosteroids, 86 (48%; 95% CI 41%–56%) had a response with two-point reduction or more. Factors that significantly predicted responses were performance status score of 3 or more, Palliative Performance Scale score more than 40, absence of ascites, absence of drowsiness, absence of depression, serum albumin level greater than 3 mg/dL, serum sodium level greater than 135 mEq/L, and baseline NRS score greater than 5. A multivariate analysis showed that the independent factors predicting responses were baseline NRS score greater than 5 (odds ratio [OR] 6.6, 95% CI 2.8–15.4), Palliative Performance Scale score more than 40 (OR 4.4, 95% CI 2.1–9.3), absence of drowsiness (OR 3.4, 95% CI 1.7–6.9), absence of ascites (OR 2.3, 95% CI 1.1–4.7), and absence of pleural effusion (OR 2.2, 95% CI 1.0–5.0). Conclusion Treatment responses to corticosteroids for CRF may be predicted by baseline symptom intensity, performance status, drowsiness, and severity of fluid retention symptoms. Larger prospective studies are needed to confirm these results.

AB - Context Although corticosteroids are widely used to relieve cancer-related fatigue (CRF), information regarding the factors predicting responses to corticosteroids remains limited. Objectives The aim of this study was to identify potential factors predicting responses to corticosteroids for CRF in advanced cancer patients. Methods Inclusion criteria for this multicenter, prospective, observational study were patients who had metastatic or locally advanced cancer and had a fatigue intensity score of 4 or more on a 0–10 Numerical Rating Scale (NRS). Univariate and multivariate analyses were conducted to identify the factors predicting two-point reduction or more in NRS on day 3. Results Among 179 patients who received corticosteroids, 86 (48%; 95% CI 41%–56%) had a response with two-point reduction or more. Factors that significantly predicted responses were performance status score of 3 or more, Palliative Performance Scale score more than 40, absence of ascites, absence of drowsiness, absence of depression, serum albumin level greater than 3 mg/dL, serum sodium level greater than 135 mEq/L, and baseline NRS score greater than 5. A multivariate analysis showed that the independent factors predicting responses were baseline NRS score greater than 5 (odds ratio [OR] 6.6, 95% CI 2.8–15.4), Palliative Performance Scale score more than 40 (OR 4.4, 95% CI 2.1–9.3), absence of drowsiness (OR 3.4, 95% CI 1.7–6.9), absence of ascites (OR 2.3, 95% CI 1.1–4.7), and absence of pleural effusion (OR 2.2, 95% CI 1.0–5.0). Conclusion Treatment responses to corticosteroids for CRF may be predicted by baseline symptom intensity, performance status, drowsiness, and severity of fluid retention symptoms. Larger prospective studies are needed to confirm these results.

KW - cancer

KW - corticosteroids

KW - Fatigue

KW - palliative care

KW - predictors

UR - http://www.scopus.com/inward/record.url?scp=84991221958&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991221958&partnerID=8YFLogxK

U2 - 10.1016/j.jpainsymman.2016.01.015

DO - 10.1016/j.jpainsymman.2016.01.015

M3 - Article

VL - 52

SP - 64

EP - 72

JO - Journal of Pain and Symptom Management

JF - Journal of Pain and Symptom Management

SN - 0885-3924

IS - 1

ER -